Design, synthesis and pharmacological screening of b-amino-, thiadiazole/thiadiazine-phosphonate based triazole motifs as antimicrobial/cytotoxic agents Three different series of phosphonate derivatives, b-aminoand fused thiadiazolo/thiadiazine-phosphonates have been synthesized using the addition and/or addition-cyclization protocol of Horner-Wadsworth-Emmons (HWE) reagents to 1,2,4-triazole-3-thiols. The design of potentially antimicrobial and anticancer phosphor esters relied on the results of computer-assisted molecular modeling. All synthesized phosphonates were evaluated for their in vitro antimicrobial activities while anticancer properties were determined for eight out of twenty new phosphonates. The tested phosphonates, except for compounds that have a nitrile moiety, exhibited moderate to significant antimicrobial activity. Nevertheless, the most active compounds were fused thiadiazole-phosphonates, which inhibited the growth of both Gram-negative and Gram-positive bacteria better than b-aminophosphonates and fused thiadiazolophosphonates. In parallel, the antitumor activity screenings of selected phosphonates from each series and substra te 1 were also done. Their antitumor properties against ten carcinoma cell lines, including breast (MCF7, MDA-MB-231/ ATCC, MDA-MB-435, BT-549), ovarian (IGROVI, OVCAR-3, SK-OV-3), prostate (PX-3, PU-145), and liver (HEPG2), were investigated. The results showed that all synthesized compounds reflected remarkable antitumor activity against breast (especially MDA-MB-231/ATCC and BT-549), and pro state carcinoma cell lines (PC-3 and DU-145), whereas a moderate to good effect on ovarian and liver cancer cells was observed.
ria and fungi (1) . In addition, cancer is among the most critical health issues and is considered to be the second leading cause of death, just after circulatory diseases. Despite the availability of improved drugs, including targeted cancer therapies, according to the World Health Organization (WHO), the worldwide cancer burden is expected to increase by as much as 50 % by the year 2020 unless further preventive measures are put into practice (2) . These trends have emphasized the urgent need for new, more effective and safe antimicrobial and/or antitumor drugs that may have dual/multiple action towards biological targets (3, 4) .
Chemistry of N-bridged heterocyclic compounds, such as triazoles, especially 1,2,4-triazoles, has received considerable attention in recent years due to their biological ac tivities. However, a number of biological activities such as antiinflammatory, analgesic and others are associated with the N-substituted 1,2,4-triazole nucleus attached with different heterocycles (5, 6) . Furthermore, over the last two decades, a continuous trend is observed toward the chemistry of N,P-heterocycles and derived phosphonates, largely, because these compounds tend to have high antibiotic (7) and antitumor potencies (8) . Moreover, the 1,2,4-triazole nucleus has been incorporated into a wide variety of therapeutically important agents. Ribavirin, posaconazole, fluconazole and itraconazole are efficient antibacterial and/or antifungal drugs used in current treatments (9) . Further, vorozole, letrozole and anastrozole are some examples of antitumor drugs containing the 1,2,4-triazole moiety (10) . In view of these observations and our program of synthesis of 5-membered N-heterocycle phosphor esters with antibiotic (11) (12) (13) and anticancer properties (14-16), we report herein the synthesis of three series of b-amino-, fused thiadiazolo-, and thiadiazino-phosphonate-based 1,2,4-triazole motifs. Optimized antimicrobial and cytotoxic activity of newly-synthesized phosphonates was based on potency prediction using the computerassisted molecular modeling (CAMM) (17, 18) . EXPERIMENTAL 
General
Melting points were determined with an open capillary tube on an Electrothermal (variable heater, Stuart, UK) melting point apparatus and were corrected. IR spectra were recorded on a JASCO FT-IR 6100 using a KBr disc (JASCO, Japan). NMR spectra were measured with a JEOL E.C.A-500 MHz ( 13 C: 125.4 MHz, 1 H: 500.7 MHz, 31 P: 200.7 MHz) spectrometer (JEOL, Japan).
31
P NMR spectra were recorded with H 3 PO 4 (85 %) as external reference, 1 
H and
13 C NMR spectra were recorded with trimethylsilane as internal standard in CDCl 3 . Chemical shifts (d) are given in ppm. Mass spectra were recorded at 70 eV on an MS-50 Kratos (A.E.I.) spectrometer (Kratos, UK). Elemental analyses were carried out at the Microanalysis Laboratory, Cairo University. Elemental analyses were performed using elementary Analysensysteme GmbH-vario EL III Element Analyzer (Germany). Compounds 4-(4-(dimethylamino)benzylideneamino)-4H-1,2,4-triazole-3-thiol (1) and 4-(4-chlorobenzylidene-amino)-4H-1,2,4-triazole-3-thiol (2) were obtained using the procedures reported elsewhere (19, 20) . Phosphonyl carbanion reagents: [diethyl (2-amino-2-thioxoethyl)-, diethyl cyanomethylphosphonate, methyl diethyl-, triethyl phosphonoacetate, diethyl (methylthiomethyl)phosphonates, diethyl (methylthioethyl)phosphonate and diethyl 2-methylallylphosphonate] were purchased from Sigma-Aldrich Company (USA).
General synthesis procedure
Synthesis of 3a-h and 4a-h. -A solution of LiH (0.1 g, 12.6 mmol) in DMF (20 mL) and the phosphonyl carbanion (4.2 mmol) [diethyl (2-amino-2-thioxoethyl)-, diethyl cyanomethylphosphonate, methyl diethyl-or triethyl phosphonoacetate] was stirred at 0 °C for about 0.5 h. A solution of 1 (0.86 g, 3.5 mmol) or 2 (0.83 g, 3.5 mmol) in 10 mL of DMF was then added in one portion. After the evolution of H 2 had ceased, the suspension was stirred at room temperature for further 30 min and then heated under reflux for appropriate time (≈6 h, TLC). After completion of the reaction, the produced mixture was cooled, poured into ice-water, and acidified with HCl (1 mol L -1 ) to pH ≈5, followed by extraction with ethyl acetate (3×50 mL). The combined organic phase was dried over anhydrous Na 2 SO 4 . After removal of the volatile material under vacuum, the resulting residue was chromatographed on silica gel with n-hexane/CHCl 3 (7:3, V/V) to give the corresponding products 4a-h, followed by elution with n-hexane/CHCl 3 (1:1, V/V) to give 3a-h.
When the above reactions (1/2 with the same phosphorus reagents) proceeded in MeOH solution containing sodium methanoate (MeONa) and a catalytic amount of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), thiadiazolo-phosphonates 4a-h were exclusively obtained in 75-80 % yield.
Reaction of 1/2 with diethyl (methylthiomethyl)phosphonate and diethyl (methylthioethyl) phosphonate
Synthesis of 6a and b. -According to the general procedure, a mixture of 1 (0.86 g, 3.5 mmol), diethyl (methylthiomethyl)phosphonate (0.83 g, 4.2 mmol) or diethyl (methylthioethyl)phosphonate (0.89 g, 4.2 mmol), 0.1 g of sodium (8.4 mmol), and a catalytic amount of DDQ in 20 mL MeOH was stirred at room temperature for half an hour. The reaction mixture was further refluxed for ≈6 h (TLC) to give a material that was assigned thiadiazine-2-phosphonate (6a).
The same procedure and addition of the same amounts to the reaction of 2 with diethyl (methylthiomethyl)phosphonate (0.83 g, 4.2 mmol) or diethyl (methylthio-ethyl)phosphonate afforded the corresponding thiadiazine-2-phosphonate 6b.
Reaction of 1/2 with diethyl 2-methylallylphosphonate
Synthesis of 8a,b. -Following the general procedure and using the same amounts, 1/2 reacted with diethyl 2-methylallylphosphonate (0.80 g, 4.2 mmol) in the presence of DDQ to give phosphonates 8a or 8b after heating under reflux for 8 h.
Solvents of crystallization, yields, physical analytical data and spectral data (MS, IR, 
Pharmacology
Biological activity spectra prediction. -Biological activity spectra were predicted for substrates 1/2 and synthesized structures 3a-h, 4a-h, 6a,b, 8a and b with the molecular assisted program PASS 2009.1 version (IBMC, Moscow, Russia). The prediction result is pre- Solvents for crystalization: 
sented as a list of activities in a table available as a supplementary document. The analysis of biological activity spectra prediction is an example of the in silico study of chemical compounds before experimental investigations. The biological activity spectrum for a substance is a list of biological activity types for which the probability to be revealed (Pa) and the probability to be inactive (Pi) are demonstrated. Pa and Pi values are independent and their values vary from 0 to 1. PASS results showed that the antimicrobial and anticancer activities are the most common properties of the tested compounds.
Antimicrobial activity. -The antimicrobial activity of the synthesized phosphonates 3a-h, 4a-h, 6a,b, 8a and b was individually tested against a panel of Gram-positive and Gram-negative bacterial pathogens Klebseilla peunomoniae 2011E, Pseudomonas aeruginosa 6065 Y, Escherichia coli BW54, Escherichia coli BW55, Acinetobacter haemolyticus BW62, Steno- 
a Concentration of each used compound is 10 µmol L -1 (DMSO). b Compounds with < 3 mm growth inhibition zone were considered inactive.
trophomonas maltophilia D457R, Staphylococcus epidermis 887E, Bacilllus cereus ATCC 11778, Staphylococcus aureus ATCC 29213 and Sacrina lutea. Ciprofloxacin (Cipro) and chloramphenicol (Chlor) were used as positive reference standards. Test compounds and drugs were used at a concentration of 10 µmol mL -1 (DMSO). Antimicrobial tests were carried out by the agar well diffusion method (21) using 100 L -1 of a suspension of the proper LB nutrient broth containing 1 × 10 8 CFU mL -1 bacteria. The antimicrobial activity was evaluated by measuring the zone of inhibition against the tested organisms and compared with that of the standards. Antimicrobial activities were expressed as the inhibition diameter zones in millimeters (mm) and are presented in Table III . Each experiment was carried out in triplicate and the average zone of inhibition was calculated. 
Minimal inhibitory (MIC) and minimal bactericidal concentration (MBC)
. -The bacteriostatic activity of the most active compounds 3a,e, 4a,c,e and g as well as the two reference drugs Cipro and Chlor was determined by the broth microdilution method on 96-well polystyrene flatbottom microtiter plates (Sarstedt, Germany
and the negative controls (medium only). The lowest concentration showing no growth was taken as the minimum inhibitory concentration (MIC).
MIC was recorded as the lowest concentration of the compound that did not result in an absorbance at 595 nm that was higher than its respective control with compound after 24 h of incubation at 37 °C. Each assay was performed in triplicate. A strain is considered multiresistant when it is non-susceptible to at least 3 different classes of antimicrobial agents.
After 24 h of incubation, a spotting assay was performed in order to evaluate the minimum bacterial concentration (MBC). Plates were prepared using LB nutrient broth solid medium, dried in a laminar flux chamber and inoculated with 5 mL of the content of each microplate pit. Plates were incubated at 37 °C overnight for CFU counting. MBC was recorded as the lowest concentration that did not result in an eye-observable culture in solid medium after 24 h of incubation. Each assay was performed in triplicate.
Data of MIC / MBC are presented in Table IV .
Antitumor activity screening. -Antitumor potency of selected phosphonates 3a,c, 4a,c,e, g, 6a and 8a in addition to substrate 1 was tested at a dose of 10 mmol L -1 (DMSO) utilizing 10 different human tumor cell lines. These lines represent breast [MCF7, MDA-MB-231/ ATCC, MDA-MB-435, BT-549), ovarian (IGROVI, OVCAR-3, SK-OV-3), prostate (PX-3, PU-145), and liver (HEPG2) cells. Adriamycin (Adr) was used as a reference standard according to the reported methods (24, 25) . Using absorbance measurements at 515 nm for each compound, for control growth and for test growth, the percent growth inhibition was calculated at each of the tested compound concentration level. Susceptibility testing assays were undertaken three times. Growth inhibition of 50 % (GI 50 ) was calculated. Further studies on experimental tumors in vivo for evaluating the possible antineoplastic potential of the most promising compounds are in progress. 
), Ciprociprofloxacin, Chlor -chloramphenicol.
RESULTS AND DISCUSSION

Chemistry
Starting reaction sequences for the title compounds, b-amino-and fused thiadiazoloand thiadiazinephosphonates, are outlined in Schemes 1-3. Upon treatment with HornerWadsworth-Emmons (HWE) reagents (diethyl 2-amino-2-thioxoethyl-, cyanomethylphosphonate, methyl diethyl phosphonoacetate or triethyl phosphonoacetate), in DMF con taining LiH, 1,2,4-triazol-3-thiol substrates (1/2) yielded, after heating for appropriate time (≈6 h), the desired compounds 3a-h and 4a-h. b-Amino-phosphonates 3a-h (≈55 % yield) were obtained via nucleophilic addition reaction that led to hydrophosphonylation of the imine function in 1/2. In the IR spectra of 3a-h, NH and SH bands were observed at about 3434-3315 and 2480-2356 cm Obviously, while the nucleophilic addition of methylene-C in phosphonate reagents gave rise to products 3a-h, the slight homo-oxidation (air-oxidation) of 3 resulted in the formation of thiadiazoles 4 via intramolecular cyclization in tandem extrusion of a hydrogen molecule (27, 28) . H-bond process was reported for the transformation of 3,5-di-tertbutyl-2-hydroxyphenylamino derivatives to the corresponding benzoxazoles (14, 26) . Further, the air-oxidation process was previously discussed for the transformation of 4{[(4-chlorophenyl)methylene]-amino}-3-mercapto-methyl-3,4-dihydro-1,2,4-triazin-5(2H)-one to the respective fused pyrazoles (27) . Thiadiazoles 4 were, however, exclusively obtained in 75-80 % yield when the above reactions [1/2 and the same WHE reagents] proceeded in a methanol solution containing MeONa and a catalytic amount of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (29) .
In contrast to the above results, reactions between 1/2 and diethyl [methyl(thioalkyl)] phosphonates proceeded only when a catalytic amount of DDQ was present in the medium (best yield, MeOH/MeONa/DDQ) and yielded, in each case, the same product, thiadiazine-2-phosphonates 6a,b (≈72 % yield). As displayed in Scheme 2, compounds 6a,b were formed via elimination of the alkylthiol motif from the initial intermediate 3i, followed by intramolecular cyclization. Structure 6a showed strong absorption bands at ν max 3415 (NH), 1262 (P=O), and at 1115 (P-O-C) and disappearance of the band at 2420 cm -1 due to the SH group. The 
Pharmacology
Antimicrobial evaluation. -Preliminary screening of new compounds 3a-h, 4a-h, 6a,b, 8a and b was evaluated in vitro against a panel of standard and clinically isolated strains of the Gram-negative and Gram-positive bacteria using the disc diffusion method and the results are presented in Table III . All tested phosphonates, except the compounds 3b,f, 4b and f (compounds that have a nitrile moiety), exhibited some antimicrobial activity. Measurement of the zone of growth inhibition for 10 mmol mL -1 (DMSO) of each compound showed that the most active compounds were the fused thiadiazole-phosphonates 4a,c,e and g, which inhibited the growth of Gram-negative and Gram-positive bacteria. The most active compounds were selected for further screening. They all have in common the fusedthiadiazole ring, which suggests that the presence of this motif may be enhancing the activity. Even compounds 3a and 3e, which were less active, were also selected. MIC and MBC were then determined for the lead phosphonates 3a,e, 4a,c,e and g, as well as two reference drugs ciprofloxacin and chloramphenicol. The activity was assessed for each drug in the range of concentrations from 450 to 10 mmol L -1 (450, 200, 100, 50, 25, 10 mmol L -1 ) in cation-adjusted Mueller Hinton medium (22) and the results are presented in Table IV .
The data displayed in Tables III and IV Antitumor activity. -Inspired by the optimized results of the prediction analysis, antitumor activity screening of 3a,c, 4a,c,e,g, 6a and 8a was tested applying carcinoma cell lines against adriamycin as a reference standard at a dose of 10 µmol L -1 (DMSO). Substrate 1 was also tested at the same dose in a trial to reflect the effect of introducing phosphonate derivatives. The results are displayed in Table V and show an interesting activity for several compounds. With the exception of substrate 1, all synthesized compounds reflected remarkable antitumor activity against breast (especially MDA-MB-231/ATCC and BT-549) and prostate carcinoma cell lines (PC-3 and DU-145), whereas a moderate to good effect was observed on ovarian and liver cancer cells. The order of activity for the tested compounds is: 3a > 3c > 4a > 4e > 4c > 4g > 6a > 8a. Structure-activity relationship correlation for these compounds revealed that the presence of dialkylamino or 4-chloro as a substitu- a Cell line growth inhibition with > 50% at a concentration of 10 mg L -1 was considered to be a noticeable activity. b NA: not active. Data are presented as the means Standard Deviation (± SD) of three independent experiments. ent on the aryl-moiety or as a substituent on the phosphonate moiety, is usually associated with enhancement of the antitumor property, as indicated in compounds 3a,c, 4a and in 4e and 4g. In contrast to the antibiotic results, the data showed that the b-aminophosphonates 3a and c possess higher activity than their cyclic thiadiazole-counterparts 4a and c. In gene ral, compounds 3a, in particular 4e and 4g showed more significant antitumor activity against tested carcinoma cell lines than the standard drug adriamycin. However, no straight correlation between the tumor activity and antibiotic efficacy of b-aminophosphonates and thiadiazoles or thiadiazines was found. This result is not surprising, since the targets of these two activities should be different. Further, the observed antibacterial activity, albeit weak, can be the result of non-specific cytotoxic effects (e.g., 6a and 8a), since bac teria can be killed in many ways.
CONCLUSIONS
We have developed a simple and convenient procedure for the preparation of a range of b-aminophosphonates 3a-h, fused-thiadiazole-5-methylphosphonates 4a-h and thiadiazinephosphonate derivatives from readily prepared 4-(4-(arylideneamino)-4H-1,2,4-triazole-3-thiols 1/2. The antimicrobial evaluation showed that the most active compounds are the fused thiadiazole-phosphonates 4a,c,e and g, which inhibited the growth of Gram--negative and Gram-positive bacteria. On the other hand, the order of the antitumor properties for the tested selected compounds is: 3a > 3c (b-aminophosphonates) > 4a > 4e > 4c > 4g (thiadiazolemethylphosphonates) > 6a > 8a (thiadiazine-phosphonates).
